Trial Profile
Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 17 Oct 2023 Planned End Date changed from 1 Apr 2024 to 1 Oct 2025.
- 17 Oct 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Oct 2025.
- 28 Feb 2023 Planned End Date changed from 1 Dec 2023 to 1 Apr 2024.